Search Results
Nov 11, 2025, 09:00 ET True Global Ventures celebrates two major portfolio milestones in 72 hours, marking a defining moment in the U.S.
education to finance and beyond — to an even broader audience." He continued: "Our collaboration with Currenc reflects shared DNA — both organizations are reinventing how value moves globally. Together, we aim to accelerate the transition toward open, interoperable digital economies.
More news about: True Global Ventures
Nov 11, 2025, 09:00 ET Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
ISO13485 Quality Management System certification. The company was the first in China to achieve large-scale production of the DNA "molecular scissors" – restriction endonucleases, breaking the complete monopoly of foreign companies for over 40 years. It currently ranks among the
More news about: Sanyou Bio
Nov 11, 2025, 08:40 ET INOVIO Announces Pricing of $25 Million Public Offering
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 18:09 ET INOVIO Announces Proposed Public Offering
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
with other immunotherapies or cancer treatments. Inovio Pharmaceuticals and MedImmune's INO-3112 is a DNA-based therapeutic candidate targeting HPV types 16 and 18, paired with a plasmid encoding IL-12 to enhance immune activation. INOVIO is studying INO-3112's
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 16:23 ET Three Five Star Franchising brands named 2025 Top Franchises for Veterans by Entrepreneur
99) reflects both brand-level excellence and a company-wide dedication to supporting those who have served. "It's part of our DNA to help people build strong businesses that make a real impact in their communities — and no group embodies that spirit more than our veterans," said
More news about: Five Star Franchising
Nov 10, 2025, 16:05 ET INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
About INOVIO's DNA Medicines PlatformINOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 15:45 ET Ancient Genes May Explain Why Heart Disease Is So Common Today
Thomas. The Double-Edged Sword of Evolution Advances in ancient DNA sequencing have provided new clues. In 2023, Zink and colleagues found that Ötzi carried more than 60% of known genes associated with atherosclerosis
More news about: Memorial Health Services
Nov 10, 2025, 12:37 ET BMC Helix a Leader in 2025 Enterprise Service Management (ESM) Report by Independent Research Firm
management." "Being named a leader in this influential report isn't just recognition. For us, it's proof that playing it safe isn't in our DNA. We believe BMC Helix received the highest scores possible in the vision, innovation, and roadmap criteria because we refuse to follow trends—we set
More news about: BMC Helix
Nov 10, 2025, 12:15 ET Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
Production System and a commercially available 3-plasmid system, with no negative effects on quality parameters such as vg/cap ratio or mispackaged DNA being observed. Enhancer activity was further confirmed using customer plasmids. Enhancer
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
Production System and a commercially available 3-plasmid system, with no negative effects on quality parameters such as vg/cap ratio or mispackaged DNA being observed. Enhancer activity was further confirmed using customer plasmids. Enhancer
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend stellt proprietäre Enhancer vor, die die AAV-Ausbeute deutlich verbessern, ohne die Qualität zu beeinträchtigen
3-Plasmid-Systems in mehreren Maßstäben getestet, ohne dass negative Auswirkungen auf Qualitätsparameter wie das vg/cap-Verhältnis oder falsch verpackte DNA beobachtet wurden. Die Enhancer-Aktivität wurde anhand von Kundenplasmiden weiter bestätigt. Es
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET REIMAGINED FOR PREMIUM LIVING AND RUGGED ADVENTURE: KIA REVEALS THE NEXT-GENERATION 2027 TELLURIDE SUV
for the brand's design and ambition Telluride blends Kia's Opposites United design philosophy with its own signature design DNA Global debut set for 2025 Los Angeles Auto Show IRVINE,
More news about: Kia America
Nov 10, 2025, 11:50 ET New England Biolabs® announces a full lineup of events supporting the AMP 2025 Annual Meeting & Expo in Boston, MA
SamplesPresenter: Margaret R. Heider, Ph.D. Poster #TT065: NEBNext Enzymatic Solutions for DNA Methylation Profiling of Highly Damaged DNA InputsPresenter: Vaishnavi Panchapakesa, Ph.D.
More news about: New England Biolabs, Inc.
Nov 10, 2025, 11:38 ET Scala Data Centers, Lightera e Nokia realizam o primeiro teste AccuCore HCF™ (Hollow Core Fiber) na América Latina
digital, aproximando as velocidades de transmissão dos limites físicos da luz. "A inovação está em nosso DNA. Permitir o primeiro teste de fibra de núcleo oco nas Américas reforça o papel da Scala como uma plataforma de ponta para a transformação digital e nos
More news about: Scala Data Centers
Nov 10, 2025, 11:29 ET CYBEX OPENS THE FIRST FLAGSHIP STORE IN NEW YORK
complemented by elegant gold racks that add a touch of sophistication. The store's sleek, modern aesthetic creates a dialogue between CYBEX's signature design DNA and the distinctive character of New York City. This carefully crafted space is designed to foster an intimate and inspiring shopping experience, also
More news about: CYBEX
Nov 10, 2025, 10:50 ET ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
claims across all cell types. Derived from a bacterial immune defence system, CRISPR/Cas9 is a precise, efficient tool for editing DNA in living organisms that has transformed research across genetics, biotechnology, and molecular biology. ERS Genomics offers non-exclusive
More news about: ERS Genomics
Nov 10, 2025, 10:00 ET Cereal in Culture: Froot Loops Taps Jeweler Kristopher Kites to Design One-of-a-Kind Wearable Art Inspired by Iconic Hip-Hop Lyrics
@frankmorrison] Each artist's poster, inspired by the hip-hop DNA that is uniquely ingrained in the cities, hides a clue tied to a classic hip-hop name drop of Froot Loops. Brittney Price, the
More news about: WK Kellogg Co.
Nov 10, 2025, 09:58 ET Taste of Bionics - Ottobock launches podcast hosted by Ranga Yogeshwar
bionics landscape of the future. The mission of improving people's freedom of movement, quality of life and independence is deeply rooted in the company's DNA – as is its social commitment: Ottobock has been a partner and supporter of the Paralympic Games since 1988.
More news about: Ottobock
Nov 10, 2025, 08:38 ET The DNA Company Named Functional Genomics Innovation of the Year for the 2025 BioTech Breakthrough Awards
globe. The DNA Company was awarded for their efforts in redefining how genetics are applied in everyday life through their DNA 360 test and comprehensive genomic reports. Unlike traditional genetic testing, which focuses on disease risk, The DNA Company's functional genomics approach
More news about: The DNA Company
Nov 10, 2025, 08:16 ET Personalized Cancer Insights, Grounded in Biology, DNA/RNA & AI Delivered in an Average of 10 Days
research over large patient populations. However, if we know biologically each person is unique, then a consensus-based treatment plan may not work. DNA and RNA sequencing, biomarker identification, and targeted therapies began being offered to cancer patients in the late 1990s and early 2000s and can
More news about: First Ascent Biomedical
Nov 10, 2025, 08:15 ET Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
EST The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Reduces Oxidized Mitochondrial DNA in Patients with Low-Risk Myelodysplastic SyndromeSaturday, December 6, 2025; 5:30 P.M. – 7:30 P.M. EST
More news about: Halia Therapeutics
Nov 10, 2025, 08:15 ET Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
EST The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Reduces Oxidized Mitochondrial DNA in Patients with Low-Risk Myelodysplastic SyndromeSaturday, December 6, 2025; 5:30 P.M. – 7:30 P.M. EST
More news about: Halia Therapeutics
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
demonstrating structural biology research that reveals for the first time a DNA pol IIIC inhibitor, ibezapolstat, bound to its target. The publication is entitled: A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens. The senior author
More news about: Acurx Pharmaceuticals, Inc.